CMTx Biotech, Inc.

United States · 8 Employees
CMTx Biotech is commercializing a pipeline of proprietary, non-antibiotic, chemically-modified tetracycline (CMT) compositions and formulations for the host-modulatory treatment of diseases with high unmet needs. The company's lead drug candidate is a clinical-stage, orally-administered small molecule (incyclinide / CMT-3 / COL-3) for the treatment of hospitalized sepsis patients at risk of septic shock, multiple organ dysfunction syndrome (MODS) and acute respiratory distress syndrome (ARDS), including from SARS-CoV-2 infection (COVID-19) and other infectious diseases. Our clinical-stage drug candidate has already demonstrated impressive efficacy in a number of animal models of sepsis/ARDS/MODS across multiple species (rats, mice, pigs, sheep). It has also been evaluated in over 450 patients across eleven Phase I/II clinical studies, which showed that the drug is well-tolerated. CMTx Biotech also has a pipeline of pre-clinical stage analogues for the treatment of diseases with high unmet need.

概述

国家 United States
成立时间 2019
总部 25 health sciences dr, stony brook, new york, united states
电话号码 +1 631-258-5680
网站 http://www.cmtxbiotech.com
LinkedIn http://www.linkedin.com/company/cmtx-biotech-inc
Twitter
Facebook
员工数 8
行业 biotechnology,
简介 CMTx Biotech is commercializing a pipeline of proprietary, non-antibiotic, chemically-modified tetracycline (CMT) compositions and formulations for the host-modulatory treatment of diseases with high unmet needs. The company's lead drug candidate is a clinical-stage, orally-administered small molecule (incyclinide / CMT-3 / COL-3) for the treatment of hospitalized sepsis patients at risk of septic shock, multiple organ dysfunction syndrome (MODS) and acute respiratory distress syndrome (ARDS), including from SARS-CoV-2 infection (COVID-19) and other infectious diseases. Our clinical-stage drug candidate has already demonstrated impressive efficacy in a number of animal models of sepsis/ARDS/MODS across multiple species (rats, mice, pigs, sheep). It has also been evaluated in over 450 patients across eleven Phase I/II clinical studies, which showed that the drug is well-tolerated. CMTx Biotech also has a pipeline of pre-clinical stage analogues for the treatment of diseases with high unmet need.

技术

Amazon AWS

Hosting

Android

Frameworks and Programming Languages

Gmail

Email Providers

Google Apps

Other

Google Tag Manager

Tag Management

Mobile Friendly

Other

常见问题

CMTx Biotech, Inc. 在哪里?

CMTx Biotech, Inc. 的总部位于 25 health sciences dr, stony brook, new york, united states

CMTx Biotech, Inc. 的电话号码是多少?

CMTx Biotech, Inc. 的电话号码是 +1 631-258-5680

CMTx Biotech, Inc. 的官方网站是什么?

CMTx Biotech, Inc. 的公司官方网站是 http://www.cmtxbiotech.com

CMTx Biotech, Inc. 是做什么的?

CMTx Biotech, Inc. 的业务有哪些?

CMTx Biotech, Inc. 的年收入是多少?

CMTx Biotech, Inc. 的收入是 0美元

CMTx Biotech, Inc. 有多少员工?

CMTx Biotech, Inc. 有 8 名员工

CMTx Biotech, Inc. 属于哪个行业?

CMTx Biotech, Inc. 从事以下行业: biotechnology

CMTx Biotech, Inc. 使用什么技术?

CMTx Biotech, Inc. 使用的一些流行技术包括: Amazon AWS,Android,Gmail,Google Apps,Google Tag Manager,Mobile Friendly

如何联系 CMTx Biotech, Inc.?

CMTx Biotech, Inc. 联系信息: 电话号码:+1 631-258-5680， 网站:http://www.cmtxbiotech.com， 邮箱：jsc***@***.com

CMTx Biotech, Inc. 的社交媒体链接是什么?

CMTx Biotech, Inc. 领英：http://www.linkedin.com/company/cmtx-biotech-inc,fackbook：,twitte:

CMTx Biotech, Inc. 是一家上市公司吗?

不是

CMTx Biotech, Inc. 的最后一轮融资是什么时候?

暂无最近投资信息

谁投资 CMTx Biotech, Inc.?

CMTx Biotech, Inc. 有 0 家投资者,包括 。

管理层

Joseph Scaduto

Co-Founder and CEO

员工

外贸获客 查找关键决策人

10亿+海关交易数据，1.2亿企业数据，2亿+企业联系人数据，1000千万真实采购商。覆盖200+个国家及地区，95%外贸重点拓展市场，可根据行业、经营范围等多方位挖掘目标客户。
免费试用

Top-ranked on G2 Crowd

全球B2B企业库 海关贸易数据 展会采购数据

工作更少，成就更大，销售更聪明

查找更多 B2B 联系人，丰富并验证记录
Email Address

全球B2B企业库

海关贸易数据

展会采购数据

Top-ranked on G2 Crowd

OR
Sign Up with Google